Gupta Sanjiv, Gupta Madan Mohan
SDM Hospital, Jaipur, India.
Heart and Diabetic Clinic, Jaipur, India.
Indian Heart J. 2016 Jul-Aug;68(4):539-51. doi: 10.1016/j.ihj.2016.04.006. Epub 2016 Apr 19.
Percutaneous coronary intervention (PCI) is effective in opening the infarct related artery and restoring thrombolysis in myocardial infarction flow 3 (TIMI-flow 3) in large majority of ST-elevation myocardial infarction (STEMI). However there remain a small but significant proportion of patients, who continue to manifest diminished myocardial reperfusion despite successful opening of the obstructed epicardial artery. This phenomenon is called no-reflow. Clinically it manifests with recurrence of chest pain and dyspnea and may progress to cardiogenic shock, cardiac arrest, serious arrhythmias and acute heart failure. No reflow is regarded as independent predictor of death or recurrent myocardial infarction. No reflow is a multi-factorial phenomenon. However micro embolization of atherothrombotic debris during PCI remains the principal mechanism responsible for microvascular obstruction. This review summarizes the pathogenesis, diagnostic methods and the results of various recent randomized trials and studies on the prevention and management of no-reflow.
经皮冠状动脉介入治疗(PCI)对于开通梗死相关动脉并使大多数ST段抬高型心肌梗死(STEMI)患者恢复心肌梗死溶栓血流3级(TIMI血流3级)是有效的。然而,仍有一小部分但比例可观的患者,尽管阻塞的心外膜动脉成功开通,但心肌再灌注仍持续减弱。这种现象被称为无复流。临床上表现为胸痛和呼吸困难复发,可能进展为心源性休克、心脏骤停、严重心律失常和急性心力衰竭。无复流被视为死亡或复发性心肌梗死的独立预测因素。无复流是一种多因素现象。然而,PCI期间动脉粥样硬化血栓碎片的微栓塞仍然是导致微血管阻塞的主要机制。本综述总结了无复流的发病机制、诊断方法以及近期各种关于无复流预防和管理的随机试验和研究结果。